Prelude Therapeutics Inc (NAS:PRLD)
$ 3.6 -0.02 (-0.55%) Market Cap: 197.75 Mil Enterprise Value: 13.46 Mil PE Ratio: 0 PB Ratio: 0.94 GF Score: 38/100

Prelude Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 17, 2022 / 01:00PM GMT
Release Date Price: $8.36 (+7.87%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

First and foremost, glad to see everyone in person. This is Barclays Healthcare Global Conference in Miami, so thanks everyone for coming down to Miami in person, first event for 2 years for Wall Street. So we're really excited to get to see everyone again.

And my name is Peter Lawson. I'm one of the biotech analysts at Barclays. Just wanted to thank. We have here with us from Prelude Therapeutics. We have Kris Vaddi, CEO; and Laurent Chardonnet, CFO. And thanks so much for the time. Thanks so much for your support in kind of getting this event back to in person and get us back to seeing each other again.

So I guess first point, we've got -- you've got some slides just to kind of set the scene for us, and then we'll dive into Q&A. Thank you so much.

Krishna Vaddi
Prelude Therapeutics Incorporated - Founder, CEO & Director

Thank you, Peter. Thanks for the opportunity to participate in your meeting and we're really excited to be part of -- to be here in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot